bioRxiv · 10.1101/2023.08.10.552828
Structure-based development of new cyclic compoundstargeting PSD-95 PDZ3 domain.
Abstract
Aberrant BDNF signaling has been proposed to contribute to the pathophysiology of depression and other neurological disorders such as Angelman syndrome. We have previously shown that targeting the TrkB / PSD-95 nexus by peptidomimetic inhibitors is a promising approach for therapeutic intervention. Here we used structure-based knowledge to develop a new peptidomimetic compound series that fuses SynGAP-derived peptides to our prototype compound CN2097. These compounds target the PSD-95 PDZ3 domain and adjoining C helix to achieve bivalent binding that results in up to 7-fold stronger affinity compared to CN2097. These compounds were designed to improve CN2097 specificity for the PDZ3 domain and limited SAR studies have been performed to improve their resistance to proteolysis.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Naik, M. T., Naik, N., Hu, T., Wang, S.-H., Marshall, J.. 2023-08-11. Structure-based development of new cyclic compoundstargeting PSD-95 PDZ3 domain.. https://doi.org/10.1101/2023.08.10.552828
Cite the original work for its findings. Save a collection to share your selection of sources.